• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局限性前列腺癌的根治性放疗:局部疾病持续存在会导致晚期转移浪潮。

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

作者信息

Coen John J, Zietman Anthony L, Thakral Harjot, Shipley William U

机构信息

Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA.

出版信息

J Clin Oncol. 2002 Aug 1;20(15):3199-205. doi: 10.1200/JCO.2002.01.086.

DOI:10.1200/JCO.2002.01.086
PMID:12149291
Abstract

PURPOSE

To assess whether failure to maintain local control (LC) of prostate cancer after radiation therapy results in a higher incidence of distant metastasis (DM).

PATIENTS AND METHODS

From 1972 to 1999, 1,469 patients with clinically localized prostate cancer were treated with radical radiation therapy. Disease outcome was retrospectively reviewed for all patients with more than 2 years of follow-up.

RESULTS

The actuarial 10-year LC rate was 79%. Gleason score > or = 7, prostate-specific antigen (PSA) more than 15, and T3 to T4 tumors predicted a higher incidence of local failure (LF) (palpable recurrence or positive rebiopsy). The 10-year distant metastasis-free survival (DMFS) was 74%. Gleason score > or = 7, PSA more than 15, and T3 to T4 tumors predicted a higher incidence of distant failure. LF was the strongest predictor for DM in a multivariate model. The 10-year DMFS for LC and LF patients was 77% and 61%, respectively. Median time to distant failure was prolonged in patients with LF compared with patients with locally controlled disease (54 v 34 months). Hazard rate analysis of the time to DM revealed that patients who maintain LC have a lower rate of DM, which remains constant over time. Patients who ultimately develop LF have a higher initial rate of DM, which increases with time.

CONCLUSION

Patients with locally persistent prostate cancer are at greater risk of DM. The higher initial hazard of DM is consistent either with an increased likelihood of subclinical micrometastases before treatment or with posttreatment tumor embolization. The prolonged time to appearance of DM in locally failing patients and the increasing hazard of DM over time is most consistent with a late wave of metastases from a locally persistent tumor.

摘要

目的

评估放射治疗后未能维持前列腺癌的局部控制(LC)是否会导致远处转移(DM)发生率升高。

患者与方法

1972年至1999年,1469例临床局限性前列腺癌患者接受了根治性放射治疗。对所有随访超过2年的患者的疾病转归进行回顾性分析。

结果

精算10年LC率为79%。Gleason评分≥7、前列腺特异性抗原(PSA)大于15以及T3至T4期肿瘤预示局部失败(LF,可触及复发或再次活检阳性)发生率更高。10年无远处转移生存率(DMFS)为74%。Gleason评分≥7、PSA大于15以及T3至T4期肿瘤预示远处失败发生率更高。在多变量模型中,LF是DM的最强预测因素。LC和LF患者的10年DMFS分别为77%和61%。与局部控制良好的患者相比,LF患者发生远处失败的中位时间延长(54对34个月)。对发生DM时间的风险率分析显示,维持LC的患者DM发生率较低,且随时间保持恒定。最终发生LF的患者初始DM发生率较高,且随时间增加。

结论

局部持续性前列腺癌患者发生DM的风险更高。DM的较高初始风险要么与治疗前亚临床微转移可能性增加一致,要么与治疗后肿瘤栓塞一致。局部失败患者中DM出现时间延长以及DM风险随时间增加最符合局部持续性肿瘤的晚期转移浪潮。

相似文献

1
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.局限性前列腺癌的根治性放疗:局部疾病持续存在会导致晚期转移浪潮。
J Clin Oncol. 2002 Aug 1;20(15):3199-205. doi: 10.1200/JCO.2002.01.086.
2
Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer.增加放疗剂量对局限性前列腺癌患者局部和远处复发的影响。
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):16-22. doi: 10.1016/j.ijrobp.2007.09.020. Epub 2007 Nov 8.
3
Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.辅助治疗初治患者根治性前列腺切除术后切缘阳性对前列腺特异抗原失败的影响。
BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.
4
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.前列腺癌根治性外照射放疗后前列腺特异性抗原(PSA)水平升高的预后预测因素
J Clin Oncol. 2005 Feb 1;23(4):826-31. doi: 10.1200/JCO.2005.02.111.
5
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.前列腺特异性抗原最低点可预测前列腺癌外照射放疗后的生化复发和远处转移:一项多机构分析。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50. doi: 10.1016/j.ijrobp.2005.07.006. Epub 2005 Sep 29.
6
The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology.外照射治疗的前列腺癌患者中,美国放射肿瘤学会(ASTRO)共识小组对生化失败的定义与临床结局之间的相关性。美国放射肿瘤学会。
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):267-72. doi: 10.1016/s0360-3016(98)00078-9.
7
Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.前列腺癌与放射治疗——血清前列腺特异性抗原所传达的信息
Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):23-35. doi: 10.1016/0360-3016(95)00154-Q.
8
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.在前列腺特异性抗原(PSA)时代,接受根治性放疗的局限性前列腺癌患者的治疗年份作为无复发生存的独立预测因素。
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. doi: 10.1016/j.ijrobp.2005.03.029. Epub 2005 May 31.
9
Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation.识别从全盆腔放疗中获益最大的高危临床局限性前列腺癌亚组。
Cancer J Sci Am. 1998 Nov-Dec;4(6):370-7.
10
Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.前列腺临床局限性癌体外照射放疗后疾病进展的风险率。
J Urol. 2003 Jun;169(6):2160-5. doi: 10.1097/01.ju.0000058212.00170.a0.

引用本文的文献

1
Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy - protocol for the ERADICATE study: a phase II randomised controlled trial.运动医学作为前列腺癌放疗期间的辅助治疗以提高治疗效果——ERADICATE研究方案:一项II期随机对照试验
BMC Cancer. 2025 Jan 28;25(1):160. doi: 10.1186/s12885-025-13555-9.
2
Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer.挽救性磁共振成像引导下经尿道超声消融治疗局限性放射性复发前列腺癌
Eur Urol Open Sci. 2024 Dec 5;71:69-77. doi: 10.1016/j.euros.2024.11.001. eCollection 2025 Jan.
3
Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs.
适当延迟原发性肿瘤放疗可能会导致接受 EGFR-TKIs 治疗的非小细胞肺癌患者有更好的长期总生存。
BMC Cancer. 2024 Aug 26;24(1):1053. doi: 10.1186/s12885-024-12826-1.
4
Induction of double-strand breaks with the non-steroidal androgen receptor ligand flutamide in patients on androgen suppression: a study protocol for a randomized, double-blind prospective trial.应用非甾体类雄激素受体配体氟他胺诱导雄激素抑制患者的双链断裂:一项随机、双盲前瞻性试验的研究方案。
Trials. 2023 Dec 16;24(1):809. doi: 10.1186/s13063-023-07838-4.
5
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial.基于[11C]-胆碱 PET/CT 引导的前列腺癌复发扩展淋巴结放疗:前瞻性试验中入组患者的 10 年结果。
Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):590-603. doi: 10.1007/s00259-023-06445-4. Epub 2023 Sep 25.
6
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.外照射放疗与单纯近距离放疗治疗中危前列腺癌的效果比较:NRG 肿瘤学 RTOG 0232 随机临床试验。
J Clin Oncol. 2023 Aug 20;41(24):4035-4044. doi: 10.1200/JCO.22.01856. Epub 2023 Jun 14.
7
Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy.靶向治疗的恶性胸腔积液非小细胞肺癌的失败模式及放疗探索
Front Oncol. 2023 May 19;13:974735. doi: 10.3389/fonc.2023.974735. eCollection 2023.
8
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial.基于PSMA-PET/MRI的立体定向体部放射治疗(HypoFocal-SBRT)原发性前列腺癌患者的局部剂量递增:一项随机、多中心III期试验的研究方案
Cancers (Basel). 2021 Nov 18;13(22):5795. doi: 10.3390/cancers13225795.
9
Oncologic outcome of salvage high-intensity focused ultrasound (HIFU) in radiorecurrent prostate cancer. A systematic review.挽救性高强度聚焦超声(HIFU)治疗放射性复发性前列腺癌的肿瘤学结果:系统评价。
Acta Biomed. 2021 Sep 2;92(4):e2021191. doi: 10.23750/abm.v92i3.11475.
10
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.放射性复发性高危前列腺癌的临床进展模式。
Eur Urol. 2021 Aug;80(2):142-146. doi: 10.1016/j.eururo.2021.04.035. Epub 2021 May 10.